期刊文献+

结肠癌患者血清CEA与临床病理的关系及随访价值 被引量:1

原文传递
导出
摘要 目的探讨结肠癌患者术前血清CEA与临床病理关系及其预测术后早期复发转移的价值。方法收集本院2014年1月—2015年12月收治的117例结肠癌手术患者。检测术前、术后(1个月、3个月、6个月、1年)血清CEA水平。分析其与临床病理特征及术后早期复发转移的关系。logistic分析影响肿瘤术后早期复发转移的危险因素。结果 117例结肠癌患者,术前CEA阳性45例。术后早期复发转移39例,其中术前CEA阳性患者32例。术前CEA阳性结肠癌患者肿瘤分化程度更低、TNM分期更晚、淋巴结转移率更高、更易发生脉管浸润(P<0.05),与术后肿瘤早期复发转移密切相关(P<0.05)。根治性手术能够显著降低患者血清CEA水平(P<0.05)。logistic分析显示术前CEA阳性、TNM分期、淋巴结转移是术后肿瘤早期复发转移的独立危险因素(P<0.05)。结论术前CEA阳性与结肠癌临床病理密切相关,并对术后早期复发转移判断有重要价值。
作者 薛亮
出处 《中国校医》 2016年第12期945-946,共2页 Chinese Journal of School Doctor
  • 相关文献

参考文献3

二级参考文献33

  • 1Chao Xu Zheng~1 Wen Hua Zhan~1 Ji Zong Zhao~2 Dong Zheng~3 Dong Ping Wang~1 Yu Long He~1 Zhang Qing Zheng~1 ~1Department of General Surgery,~2Laboratory of Surgery,~3Department of Medicine,First Affiliated Hospital,Sun Yat-Sen University of Medical Sciences,Guangzhou 510080,Guangdong Province,ChinaDr.Chao Xu Zheng now working as a surgeon and lecturer in the Department of General Surgery,First Affiliated Hospital,Sun Yat-Sen University of Medical Sciences,who is a Ph.D.student,having 7 papers published..The prognostic value of preoperative serum levels of CEA,CA19-9 and CA72-4 in patients with colorectal cancer[J].World Journal of Gastroenterology,2001,7(3):431-434. 被引量:25
  • 2欧阳艳,冯新利,王淑霞.AFP,CEA,CA19-9联检对消化系统恶性肿瘤的诊断价值[J].放射免疫学杂志,2004,17(4):302-303. 被引量:13
  • 3Xiao-UXu,JianYu,Hong-YuZhang,Meng-HongSun,JunGu,XiangDu,Da-RenShi,PengWang,Zhen-HuaYang,Jing-DeZhu.Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis[J].World Journal of Gastroenterology,2004,10(23):3441-3454. 被引量:43
  • 4陈虞梅,黄钢.肿瘤标志物CEA,CA50和CA19-9在大肠癌诊断中的意义[J].放射免疫学杂志,2005,18(1):8-10. 被引量:27
  • 5张连平,杨振,裴新红,僧靖静,谷元廷,僧国珍.大肠癌组织中P选择素的表达[J].郑州大学学报(医学版),2005,40(4):737-738. 被引量:2
  • 6Hurwitz H Fehrenbaeher L, Novotny W, et al. Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancer [J]. Cancer Treat Rev, 2004,30:715-717.
  • 7Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer [J]. N Engl J Med, 2004,351 (4) : 337-345.
  • 8Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study [J]. J Clin Oncol, 2004,22(2) : 229-237.
  • 9Grothey A. A comparison of XELOX with FOLFOX-4 as firstline treatment for metastatic colorectal cancer [J]. Nat Clin Pract Oncol, 2009,6( 1 ) : 10-11.
  • 10Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology [J]. J Clin Oncol, 1996,14(10) : 2843-2877.

共引文献72

同被引文献9

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部